Glurenorm (Gliquidone)

Glurenorm is indicated for use in adults with type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

• Improves fasting and post‑prandial blood glucose levels.
• Can be used as monotherapy or in combination with other antidiabetic agents such as metformin.
• May be considered when sulfonylurea therapy is appropriate and patient has adequate renal function.
• Helps reduce HbA1c levels as part of a comprehensive diabetes management plan.
• Is prescribed when a second‑generation sulfonylurea is preferred over first‑generation agents.

The safety profile of Glurenorm includes both frequent, mild reactions and less common, potentially serious events.

Common

• Low blood sugar (hypoglycemia), especially if meals are missed.
• Nausea or gastrointestinal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions such as rash, itching, or swelling.
• Hepatic dysfunction manifested by jaundice or elevated liver enzymes.

Before prescribing Glurenorm, clinicians should evaluate several patient‑specific factors to minimize risk.

• Assess renal and hepatic function; dose adjustment may be needed in impairment.
• Use with caution in elderly patients due to increased hypoglycemia risk.
• Avoid in pregnancy; classified as category C and discontinue if pregnancy occurs.
• Monitor blood glucose regularly to detect hypoglycemia early.
• Review concomitant medications that may potentiate hypoglycemia.
• Caution in patients with a history of cardiovascular disease.
• Educate patients on recognizing and managing low blood sugar symptoms.

Glurenorm can interact with other drugs, affecting its efficacy or safety.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole) that increase gliquidone plasma levels.
• Discontinuation of beta‑blockers without medical supervision, which can mask hypoglycemia signs.

Use with caution

• Co‑administration with thiazolidinediones, requiring close glucose monitoring.
• Use alongside diuretics that may alter electrolyte balance and affect insulin release.
• Combination with warfarin, as glycemic changes can influence anticoagulant control.